Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer
Conditions
- Recurrent Non-Small Cell Lung Carcinoma
- Stage IIIB Non-Small Cell Lung Cancer
- Stage IV Non-Small Cell Lung Cancer
Interventions
- DRUG: Carboplatin
- OTHER: Laboratory Biomarker Analysis
- DRUG: Paclitaxel
- BIOLOGICAL: Pembrolizumab
- OTHER: Quality-of-Life Assessment
Sponsor
Wake Forest University Health Sciences
Collaborators